MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.


Humanized Anti HER-3 Antibody

EV-20 is a humanized monoclonal antibody against HER3 (human epidermal growth factor receptor 3, also known as ErbB-3).

EV-20 inhibits both ligand-dependent/-independent HER3 activation and downstream signaling as well as formation of HER3/HER2 heterodimers; it rapidly and efficiently internalizes into HER3 expressing tumor cells following receptor binding.

EV20 treatment  (10 mg/Kg) leads to a long lasting tumor growth delay of several cell line-based xenografts models.


Indications in Oncology: cancers whose growth and progression depend on HER3, including those arising from breast, stomach, pancreas, ovary, prostate, lung, colorectum, head and neck and melanoma.






I commenti sono chiusi.